Palisade Bio (PALI) Notes Payables (2010 - 2013)
Palisade Bio (PALI) posted quarterly Notes Payables of $1.4 million for Q4 2013, up 8.05% quarter-over-quarter from $1.3 million in Q3 2013.
Powered by 
Analysis
Palisade Bio (PALI) Notes Payables (2010 - 2013) Analysis & Trends
Palisade Bio (PALI) has reported Notes Payables for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2013.
- In Q4 2013, Notes Payables changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2013 stood at $1.4 million (changed N/A YoY), while the FY2013 annual figure was $1.4 million, changed N/A from the prior year.
- Notes Payables grew to $1.4 million in Q4 2013 per PALI's latest filing, from $1.3 million in the prior quarter.
- Across five years, Notes Payables topped out at $1.4 million in Q4 2013 and bottomed at $445680.0 in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | 1.42 Mn |
| Sep 30, 2013 | 1.31 Mn |
| Jun 30, 2013 | 633,997.00 |
| Mar 31, 2013 | 445,680.00 |
| Dec 31, 2010 | 1.25 Mn |